The US Food and Drug Administration began accepting applications on 15 September 2026 for its expedited IND pilot. The programme is a key component of Operation TrialBlazer, according to the agency. The Department of Health and Human Services announced that initiative on 22 June 2026. It targets the stretch of development that ends with a first dose in humans. Applications close on 30 October 2026. The agency expects to name its cohort on 18 December 2026.
For a UK readership the detail that matters sits in the eligibility wording. The FDA says it will prioritise trials run in the United States. It will also prioritise institutions incorporated and staffed there. Five months earlier the MHRA opened its own Phase 1 acceleration route. That route excludes first-in-human trials outright.
What the expedited IND pilot actually offers
The pilot pairs a drug sponsor with a Qualified Research Institution, which the FDA shortens to QRI. A QRI may be an academic medical centre, a health network or a contract research organisation. Regulatory advisers are also listed. The institution advises the sponsor across nonclinical, manufacturing and clinical work. The FDA then reviews individual components of the IND as each one is finished. Sponsors in the pilot do not wait to assemble a complete package.
That rolling mechanism is the substance of the expedited IND pilot. The agency sets out the intended effect in its own programme documentation. Rolling review “has the potential to fundamentally change the timeline of pre-IND drug development”, it states. Issues “can be identified and resolved in real time”, the same page adds. The FDA also encourages parallel work on ethics review and site activation.
Participation changes none of the legal tests. The agency states that the expedited IND pilot “does not modify” its standards for IND review. It says the same of safe-to-proceed determinations and of clinical trial conduct. The FDA retains the power to impose a clinical hold. Sponsors who are not selected are not disadvantaged, according to the same document. They keep their usual pre-IND meeting rights.
Kyle A. Diamantas, Acting Commissioner of Food and Drugs, framed the goal beyond the filing itself. The pilot also tests whether the partnership can speed up the next stage, he said. That stage is “what happens after the FDA allows a clinical trial to proceed”, according to the agency’s announcement. That phrasing is worth holding on to. It places part of the delay after the regulatory decision.
The criteria favour US trials and US institutions
The published prioritisation criteria are specific about geography. The FDA will prioritise an institution “organized or incorporated in the United States”. It also wants “a principal place of business in the United States”. Core advisory personnel must be “located in the United States”. On the sponsor side, it prioritises a submission “for a FIH Phase 1 clinical trial”. The agency adds that the trial should “be run in the United States”.
These are prioritisation criteria rather than stated exclusions. The FDA says no single factor is determinative. Even so, a British contract research organisation does not meet the institution wording. A first-in-human study placed at a UK unit does not meet the trial wording. LSDN found no published carve-out for overseas sites as at 16 September 2026.
Other expedited IND pilot criteria narrow the field further. The candidate product must be novel and commercially intended. It must carry no existing clinical experience. Each participating sponsor brings a single IND submission. The agency puts the first cohort at eight to ten sponsor and institution pairs. It presents that number as a test rather than as a standing pathway. The agency has used capped, application-based pilots before, including the FDA PreCheck Program for domestic manufacturing.
The UK route runs the other way
The MHRA published guidance on its Phase 1, 14-Day Pilot Programme on 17 August 2026. The pilot began at the end of March 2026. It steps the first assessment cycle down from the standard 30 days towards 14 days across 2026. The stated aim is to “accelerate early phase trials without compromising safety or quality”. The guidance adds that the goal is to make “the UK more attractive for Phase 1 research”.
The eligibility list is where the contrast sharpens. The route covers Phase 1 healthy volunteer trials with satisfactory prior clinical safety data. Every proposed dose must already have been given safely in a clinical study. First-in-human trials sit on the exclusion list. So do advanced therapy investigational medicinal products, complex trial designs and novel mechanisms of action.
Capacity is bounded as well. The MHRA guidance sets out a stepwise schedule of weekly assessment slots. It moves from one slot a week and a 28-day target early in 2026. It reaches four slots a week and a 14-day target by the end of the year. Slots run first come, first served, and sponsors book by email before submitting through IRAS.
So the two schemes address opposite ends of the same phase. The expedited IND pilot exists for first-in-human submissions. The MHRA route covers a narrow band of lower-risk Phase 1 healthy volunteer trials that already have human dosing data. A sponsor planning a first dose in humans cannot use this MHRA pilot. The wider reform package does promise faster assessment of first-in-human trials, the MHRA and HRA said.
Both regulators point past their own clocks
The wider UK reform package is not in doubt. The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, SI 2025/538, were made on 28 April 2025. They came into force on 28 April 2026. The MHRA and the HRA marked the launch of the UK clinical trial reforms the day before. The Health Research Authority reported a combined regulatory and ethics assessment averaging 41 days. Set-up for studies through combined review fell from 169 days to 122 days, the regulators said.
Those are real gains. They also fall on the stage where the ABPI records the most progress. The ABPI published its UK pharmaceutical investment competitiveness report on 8 September 2026. In April 2026, “98 per cent of clinical trials received regulatory approval”, that report states. The target timeframe was 60 days. December 2025 data shows 58 per cent of industry trials opened to recruitment within 60 days of approval.
The same report records falling participation. It says recruitment to interventional industry clinical trials in the UK “has continued to decline”. The fall was “25 per cent between 2022/23 and 2024/25”. The report adds that China “now outperforms the U.S. in volumes of both phase I and III industry clinical trials”. LSDN has tracked the longer shift in Asian biopharma from supplier to source.
Speaking before the final design was published, US practitioners described the same pattern in a BioSpace report on TrialBlazer. Harpreet Singh is Chief Medical Officer at Precision for Medicine and a former FDA oncology division director. “FDA is not the primary source of most delays in early phase clinical trials”, she told the outlet. She attributed the delay to site-level issues instead.
Hilary Marston, a principal at Canal Row Advisors and a former FDA chief medical officer, took a similar line. “Until we take care of the site issues, we’re getting nowhere”, she said, as reported by BioSpace. BioSpace also reported that she was heartened by the TrialBlazer announcement. At a BIO International Convention panel in July, she said there was “no question that we’re losing Phase 1 trials”.
The numbers being compared are not the same number
The comparisons circulating this week do not measure the same thing. The FDA release refers to first-in-human trials taking up to two years in the United States. The release does not break that span down by stage. The MHRA’s 14 days is a first assessment cycle. The HRA’s 41 days is a combined regulatory and ethics review, and the 122-day figure is set-up.
LSDN publishes each figure with the clock it belongs to. None of them is directly comparable with the others. A sponsor choosing a jurisdiction weighs site readiness, cost and data quality alongside review speed. Neither pilot changes the first of those three.
What this means for UK sponsors
Three practical points follow. The expedited IND pilot window is short and closes on 30 October 2026. A UK-headquartered sponsor with a US arm and a planned US first-in-human study could still apply. The trial and the institution, not the sponsor’s nationality, carry the prioritisation wording.
The MHRA route remains available for healthy volunteer Phase 1 studies with prior human safety data. Sponsors should read the exclusion list before booking a slot. A novel mechanism or an advanced therapy product takes a trial out of scope. Bookings are limited and allocated in order of request.
The constraint the FDA pilot names alongside review is site activation. The ABPI figures suggest that is where UK time is lost. The ABPI points to 35 Commercial Clinical Research Delivery Centres and UK-wide contracting changes as measures at that stage. It reports that those centres are outperforming the wider health system on set-up.
Two markers fall at the end of 2026. The expedited IND pilot cohort is due on 18 December 2026. The MHRA is scheduled to reach its 14-day target by the end of the same month. Whether either scheme moves a first-in-human study across the Atlantic is a separate question.
